奥拉帕利联合阿比特龙对比奥拉帕利单药治疗阿比特龙进展后携带DNA损伤修复缺陷的转移性去势抵抗性前列腺癌患者:一项多中心真实世界研究
该多中心真实世界研究纳入86例阿比特龙进展后DDR缺陷的mCRPC患者,34例接受奥拉帕利联合阿比特龙,52例接受奥拉帕利单药。联合组中位PFS和OS均显著优于单药组,PSA缓解率显著更高,在DDR-PV和DDR-VUS亚组中疗效均显著更好,不良事件发生率可接受。
要点
- 阿比特龙进展后DDR缺陷mCRPC患者中,奥拉帕利联合阿比特龙较奥拉帕利单药显著延长PFS和OS。
- 联合组与单药组中位PFS为6.0 vs 3.0个月,HR 0.41(95%CI 0.25-0.67),p<0.01。
- 联合组与单药组中位OS为25.0 vs 12.0个月,HR 0.30(95%CI 0.14-0.67),p<0.01。
核心结论
- 对于阿比特龙进展后DDR缺陷的mCRPC患者,奥拉帕利联合阿比特龙较奥拉帕利单药获得更好的PFS和OS。
- 上述结果需通过大规模前瞻性随机对照试验进一步确认。
研究设计与样本
- 多中心真实世界研究,纳入86例阿比特龙进展后DDR缺陷的mCRPC连续患者,其中34例接受奥拉帕利联合阿比特龙,52例接受奥拉帕利单药。
- DDR缺陷定义为存在致病性或可能致病性变异的DDR基因(DDR-PV),或存在意义未明变异(DDR-VUS)。
- 采用Kaplan-Meier法评估PFS和OS,采用Cox比例风险模型比较两组间影响PFS和OS的潜在因素。
- 同时评估PSA缓解、各亚组治疗效果及不良事件(AE)。
主要发现
- 中位随访9个月,联合组与单药组中位PFS为6.0 vs 3.0个月,HR 0.41(95%CI 0.25-0.67),p<0.01。
- 联合组与单药组中位OS为25.0 vs 12.0个月,HR 0.30(95%CI 0.14-0.67),p<0.01。
- 联合治疗后的PSA缓解率显著高于单药治疗。
- 联合治疗在DDR-PV和DDR-VUS亚组中疗效均显著更好,且为更好PFS和OS的独立预测因素。
- 不良事件发生率可接受。
关键数值与推荐
- DDR缺陷定义为存在致病性或可能致病性变异的DDR基因(DDR-PV),或存在意义未明变异(DDR-VUS)。
- 联合组与单药组中位PFS为6.0 vs 3.0个月,HR 0.41(95%CI 0.25-0.67),p<0.01。
- 联合组与单药组中位OS为25.0 vs 12.0个月,HR 0.30(95%CI 0.14-0.67),p<0.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性研究。
- 样本量小。
- 随访时间短。
- 结果需通过大规模前瞻性随机对照试验进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Olaparib + abiraterone has a combined antitumor effect in metastatic castration-resistant prostate cancer (mCRPC), but the efficacy of this combination in patients with DNA damage repair (DDR)-deficient mCRPC progressing after abiraterone is unknown. Our aim was to compare the efficacy of olaparib + abiraterone versus olaparib monotherapy for patients with DDR-deficient mCRPC progressing after abiraterone. METHODS: The study included 86 consecutive patients with DDR-deficient mCRPC progressing after abiraterone: 34 received olaparib + abiraterone, and 52 received olaparib monotherapy. DDR-deficient status was defined as the presence of a DDR gene with a pathogenic or likely pathogenic variant (DDR-PV), or with a variant of unknown significance (DDR-VUS). We assessed progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method. Potential factors influencing PFS and OS were compared between the treatment arms using Cox proportional-hazards models. The prostate-specific antigen (PSA) response, the treatment effect across subgroups, and adverse events (AEs) were also evaluated. KEY FINDINGS AND LIMITATIONS: Median follow-up was 9 mo. In the overall cohort, median PFS and OS were significantly longer in the combination arm than in the monotherapy arm (PFS: 6.0 vs 3.0 mo; hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.25-0.67; p < 0.01; OS: 25.0 vs 12.0 mo; HR 0.30, 95% CI 0.14-0.67; p < 0.01). PSA responses were significantly higher following combination therapy versus monotherapy. Combination therapy had significantly better efficacy in the DDR-PV and DDR-VUS subgroups, and was an independent predictor of better PFS and OS. AE rates were acceptable. The retrospective nature, small sample size, and short follow-up are limitations. CONCLUSIONS: Olaparib + abiraterone resulted in better PFS and OS than olaparib alone for patients with DDR-deficient mCRPC progressing after abiraterone. These results need to be confirmed by a large-scale prospective randomized controlled trial. PATIENT SUMMARY: Our study shows that the drug combination of olaparib plus abiraterone improved survival over olaparib alone for patients who have mutations in genes affecting DNA repair and metastatic prostate cancer resistant to hormone therapy. The results provide evidence of a synergistic effect of the two drugs in these patients.
引用
- Xie J, Guo H, Dong B, et al. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study. Eur Urol Oncol. 2024. PMID: 38458891. doi:10.1016/j.euo.2024.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。